Tick-borne encephalitis: What travelers should know when visiting an endemic country.

Tick-borne encephalitis (TBE) is an acute febrile illness with neurological manifestations that is prevalent in forested areas of moderate climate in Europe and Asia. TBE virus is transmitted by ticks and rarely by unpasteurized milk and dairy products. The disease burden is attributed mainly to resulting long-term disability, especially in individuals over 50 y of age. Currently, there is no causative treatment, but a very effective vaccination is available with a good safety profile. The vaccination requires 3 basic doses to be fully effective and regular boosters afterwards. An accelerated vaccination schedule enables a patient to reach reasonably protective titres within 3 to 4 weeks from the first injection. The risk of travel-related TBE is estimated to be less than the risk of acquiring typhoid fever while visiting highly endemic regions in South Asia, but more than the risk of acquiring Japanese encephalitis, meningococcal invasive disease, or rabies. The pre-travel risk assessment of acquiring TBE should consider known risk factors which include 1) the country and regions to be visited; 2) April to November season; 3) altitude less than 1500 m above the sea level; 4) duration of stay; 5) the extent of tick-exposure associated activities including leisure and professional outdoor activities within the endemic area; and 6) age and comorbidities of the traveler. A major challenge, however, is the very low awareness of the risk of contracting TBE in those who travel to industrialized European countries.

Introduction

Tick-borne encephalitis (TBE) is an arboviral infection prevalent in forested areas of moderate climate in Europe and Asia, which manifests as an acute febrile illness with neurological impairment. TBE is caused by a tick-borne encephalitis virus (TBEV), a member of the genus Flavivirus within the family Flaviviridae. There are 3 subtypes of the virus – European/Western, Siberian, and Far Eastern subtypes.

Reservoir and vectors

Humans are generally accidental hosts for the TBE virus, and usually become infected after a tick bite or rarely by consumption of unpasteurized milk and dairy products. The vectors and at the same time reservoirs for the virus are hard ticks, namely castor bean/sheep tick (Ixodes ricinus) in Central and Eastern Europe (Fig. 1), and taiga tick (Ixodes persulcatus) in Siberia and the Far East. There is an overlap in distribution of both types of ticks in Scandinavia, the Baltic states, and the European part of Russia. The circulation of the virus in tick populations is maintained by co-feeding on small vertebrates. Rodents appear to have persistent viremia for days to weeks without developing any signs of illness and may represent an important reservoir of the virus in nature. The virus can infect all stadia of the ticks and remains with them for life, even through interstadial metamorphosis. Approximately 30% of TBE cases in people who report no history of tick bite may have become infected by hardly visible tick larvae or nymphs.

Figure 1.

Life stages of Ixodes ricinus ticks: larvae- size 0.8 mm (A), nymphs – size 1.2×1.5 mm (B), adult male - size 1.5×2.5 mm (C), unfed female – size 2×4 mm (D), and fully engorged female 7×11 mm (E). (photo by Jan Erhart).

The prevalence of TBEV in ticks in endemic areas range from 0.5% to 5%, exceptionally up to 30%, and there are pockets and hotspots with very variable proportion of ticks carrying the TBEV even within the same geographical area. The highest density of ticks can be found in forested areas and grasslands although infected ticks have been recovered in some urban parks. Overall, the risk of TBE infection after a single tick bite is estimated to be less than 1:100. Depending on the climate, there are one or two-peak seasonal patterns of TBE cases; from March to November.

Human epidemiology and endemic regions

There are about 10,000 – 15,000 cases of TBE reported annually worldwide, Russia alone accounting for nearly half of this number. Austria, southern Germany, the Czech Republic and Slovenia, along with Baltic States and southern parts of Scandinavia are the most affected regions in Europe. Endemic regions of TBE appear to have expanded recently, with Switzerland, north-eastern France and northern Italy now established as endemic locations. TBE cases are also reported from the Balkans as far as Greece. Belarus and Ukraine along with European part of Russia have endemic foci from St Petersburg in the north to Crimea in the south. In Asia, the whole of Siberia and Russian far east, northern Japan and 9 provinces in north west and north east of China constantly report cases of TBE (called locally Spring-summer meningoencephalitis in Russia and Forest encephalitis in China). Natural TBEV foci are also present in Korea (Fig. 2).

Figure 2.

Areas of TBEV distribution in the Eurasian region (A) with possible overlapping regions of other major flavivirues (WNV – West Nile virus, DENV – Dengue virus, JEV – Japanese encephalitis B virus). A map of TBEV distribution in Europe (B).

Reported incidence rates vary greatly between the countries and within their counties, from 0.7/100,000 in Austria to 55/100,000 in some regions of Latvia and 76/100,000 in Koroska region of Slovenia or similarly in Tomsk region of Russia. In general, the notified cases have increased in all endemic countries in the last 20–30 y by an appalling 400%. Therefore, one should assume the current risk for a traveler is significantly higher than has been in the recent past.

The incidence rates in resident populations cannot be extrapolated to assess the risk of infection in the unvaccinated traveler due to difference in exposure and very variable proportion of vaccinated population in various resident groups.

Unless diagnosed overseas or in non-endemic country, imported cases of TBE are usually not published, and therefore only a few cases have been published of TBE imported to the UK, the Netherlands, USA, and Australia. There are a few dozen cases of TBE imported annually from one endemic country to other endemic country, and based on this we could expect that many TBE cases may have gone undiagnosed or misdiagnosed with other infections, including other flaviviruses.

The uncertainty in quantification of TBE as travel risk has been very well documented in a recent review by Steffen and only crude estimates of incidence and prevalence extrapolated from various data sources and populations are available, with both numerators and denominators being far from precise. Such estimates use the principle of “guesstimate” calculations pioneered by Enrico Fermi (1901–1954, Nobel Prize winner in physics in 1938). Fermi's assumptions generally provide rough estimates, within the range of one log, but in situations where no better data are available, they may be used as a benchmark to be validated or modified in future studies. This method has been successfully used in other estimates of disease burden to lay groundwork for future research.

Based on reported overnight stays, it has been estimated that about 60 international travelers visiting Austria may become infected with TBE every summer, a number equal to the reported TBE cases in all Austria residents, a country with very high vaccination coverage. The risk for international travelers visiting central European region endemic for TBE is estimated to be similar to acquiring typhoid fever in highly endemic area or developing P. vivax malaria in travelers to India (1:3,000–1:25,000 travelers). Another estimate positions the risk of travel-related TBE to be less than the risk of acquiring typhoid fever while visiting highly endemic regions in South Asia, but more than the risk of acquiring Japanese encephalitis, meningococcal invasive disease, or rabies.

Diagnostics

Diagnosis of TBE is mainly achieved by serological testing, usually by detection of TBEV-specific IgM and IgG antibodies by enzyme-linked immunosorbent assay (ELISA). The antibodies are usually detectable at the beginning of the neurological phase of TBE. Serology using ELISA in non-endemic countries or in patients with a travel history to countries endemic for other flaviviruses may prove a challenge as there is significant cross reactivity with other members of the Flavivirus genus, such as West Nile virus, Japanese encephalitis virus, dengue, etc. In patients previously vaccinated against Japanese encephalitis or yellow fever this may be misinterpreted as post-vaccination titres. The most sensitive method, which can rule out false positive results from ELISA, is the virus neutralization test (VNT). However, strict biosafety regulations in a number of Western countries restrict the performance of VNT to laboratories equipped with a biosafety level 3 facility (biosafety level 4 in the United States); thus it is rarely performed during routine clinical diagnostics and largely unavailable in the non-endemic countries.

As a consequence, an alternative to a conventional TBEV VNT was developed based on the virus-like particles expressing a reporter gene. This assay does not require the work with life virus omitting the biosafety restrictions; however, it is not currently available for routine practice.

Detection of TBEV RNA in serum is limited to the viremic stage of the clinical disease in humans, usually before the onset of neurological symptoms. Thus this method is of limited importance because patients rarely seek medical advice during this phase of the illness. Recently, the presence of TBEV RNA was detected in urine in 2 of the 4 cases investigated during the neurological phase of TBE. This suggests that urine sampling for molecular detection of viral RNA during the neurological phase might represent a new diagnostic opportunity; however, this needs to be verified in a larger patient cohort.

Another challenge in diagnostics is the risk of dual infection, most frequently Borrelia burgdorferi and Anaplasma phagocytophilum, but also co-infection with Ehrlichia sp., Francisella tularensis, Coxiella burnetii, and rickettsiae have been reported.

Clinical presentation

There are 3 main clinical forms: meningitis, meningoencephalitis, and menigoencephalomyelitis (50%, 40%, and 10% of cases, respectively), and the fourth, rare but most devastating encephalomyeloradiculitis. Mortality ranges from 1% in central Europe to 5–20% in the Far East. Long term morbidity is significant, especially in the encephalitic and encephalomyelitic (and myeloradiculitic) forms, and may last from months to years, ranging from postencephalitic syndrome (cognitive impairment, poor concentration, headaches, fatigue, ataxia, neuropsychiatric disorders and mood disorders) to permanent palsies and seizures.

The disease burden estimate found an average of 3.1 disease-adjusted life-years (DALY) lost per every case, where majority (94%) of the disease burden were due to long-term or permanent neurological sequelae and only small portion due to mortality (5.5%) and a minimal fraction was due to acute illness (0.5%).

There are several features typical for TBE:

About a third of patients will not notice a tick bite. Mere exposure to outdoors in the endemic area within the incubation period of 7–28 d is sufficient to consider TBE;

About two thirds of cases have bi-phasic illness, with initial non-specific viremic illness that may show transaminitis, leukopenia and thrombocytopenia, followed by few days up to 2 weeks of complete resolution of symptoms before neurological impairment with high fevers develop;

At the onset of the second phase, leukocytes and CRP may be elevated, and serology may lag behind the clinical manifestation. Serology shows cross reactions with other flaviviruses in the IgG class;

Initial CSF studies may also reveal predominance of neutrophils and borderline lactate. Repeated lumbar puncture then shows shift to lymphocytic picture;

Brain regions mostly affected by the virus include basal ganglia, nucleus caudatus, brainstem, cerebellum and thalamus and, hence, ataxia including fine tremor with impaired balance and reduced level of consciousness are the main symptoms of encephalitis. Anterior horns of the spinal cord may be affected in the myelitic form resulting in polio-like disease with predominance of weakness in the proximal parts of the upper limbs. Imaging is usually unremarkable; however, T2 and turbo Flair sequences may show non-specific lesions in these regions;

Diagnosis is based on presence of clinical illness, proteo-cytological association in the cerebrospinal fluid and serological confirmation by either positive IgM or significant raise in IgG titres of TBE specific antibodies.

Management is only supportive, based on empirical experience and expert opinion, as there is only one case control study and no randomized trials at all. All other literature of TBE in humans includes case reports, case series and seroprevalence surveys.

Tick-bite prevention

Given the ecology of ticks and their habitats the highest risk behaviors in an endemic area include leisure outdoor activities including: camping, hiking, canoeing, biking, professional sports and activities of Scouts and Guides. Among professional exposure, the highest risk is encountered in woodcutting, forestry, farming, and military activities.

A universal vaccine against tick bites to cover all tick-borne diseases is still far away. Therefore, traditional individual protective measures need to be taken, including avoidance of exposure, wearing long sleeves and long trousers, preferably impregnated with permethrin, and treatment of exposed skin with dimethylmetatoluamide (DEET)-containing repellent every 1–2 hours, along with frequent tick checks and rapid removal of ticks with tweezers, and avoidance of unpasteurized milk and dairy products. However, all of these measures have limited effectiveness.

Vaccination

The only proven and reliable form of prevention is vaccination. In regions with high vaccination coverage, there is 80–90% reduction of cases reported.

There are 4 types of vaccine available, only one of them approved in the UK and until recently in Canada, but not in the United States (TicoVac and TicoVac Junior, a version of FSME Immun and FSME Immun Junior) (Table 1). All four vaccines are cell cultured TBEV on chick fibroblasts, inactivated by formaldehyde, adjuvanted with aluminum hydroxide, administered by intramuscular injection. Excipients include gentamicin and neomycin. Allergic reaction to eggs or any of the excipients are also the only reported contraindications of the vaccine.

Table 1.

Vaccination schedule.

Name	FSME-Immun§	Encepur	TBE Moscow	EnceVir
Virus subtype	European	European	Far Eastern	Far Eastern
Manufacturer	Pfizer, Austria	Novartis Vaccines, Germany	Chumakov Institute, Moscow, Russia	Microgen, Tomsk, Russia
Year of approval	1976	1994	1982	2001
Standard regimen (3 doses)
Dose 1	Day 0	Day 0	Day 0	Day 0
Dose 2	Month 1–3	Month 1–3	Month 1–7	Month 5–7
Dose 3	Month 9–12	Month 9–12	Month 12	Month 16–18
Rapid/accelerated regimen
Dose 1	Day 0	Day 0	N/A	Day 0
Dose 2	Day 14	Day 7		Day 21–35**
Dose 3	Month 5–12	Day 21		Day 42–70**
Dose 4	N/A	Month 12–18		Month 5–12
Pediatric use
Age range	1–15 years	1–12 years	From 3 y of age	From 3 y of age
Pediatric formulation	FSME-Immun Junior (half of adult dose)	Encepur-Children (half of adult dose)	Same dose as adultss	N/A, recommended to half the adult dose
Ongoing protection
Booster	Every 5 years	Every 5 years	Every 3 years	Every 3 years
Booster in >60 y of age	Every 3 years	Every 3 years	Every 3 years	Every 3 years
Availability	EU, Russia, Canada	EU, Russia	Russia, Ukraine, Kazakhstan, Belarus	Russia, Ukraine, Kazakhstan, Belarus

Marketed as TicoVac and TicoVac Junior in the UK and Canada;

from 6 months of age in high risk areas;

double dose. Adapted from Kollaritsch et al. 2011.

The vaccines are in general well tolerated, with only local reaction at the site of injection and short-lasting raised temperature. No serious or life threatening side effects have been reported in clinical trials and in post-marketing monitoring. The Western-subtype-derived vaccines induce protection for the other two, Siberian and Far Eastern subtypes. Both vaccines based on the European strains are interchangeable during a course of vaccination.

Rapid or accelerated schedules for travelers are available depending on the choice and availability of TBE vaccine; the manufacturers recommend either an accelerated schedule of immunization on Day 0, Day 14 and Month 5–7, or rapid schedule of immunization on Day 0, Day 7 and Day 21. The effectiveness of the Western vaccines reaches over 90% in rapid/accelerated schedule after 2 doses and nearly 100% after 3 doses with rapid decline in titres requiring finishing full vaccination regimen. Therefore, there is a need to finish the full schedule – both in children and adults.

Risk stratification

Based on the available data, only those who are at risk of significant tick exposure should be vaccinated before traveling to the endemic area. The pre-travel risk assessment should additively consider the following risk factors:

Region, country and region to be visited (see map of endemic areas, Fig. 2);

Season (high risk from April to November); and,

Lower altitude (less likely in altitude over 1500 m above the sea level).

Outdoor activity and its extent (both leisure and professional);

Duration of stay (the longer stay, the higher risk of an infected tick bite, as it is a stochastic event);

Higher age/comorbidities (as in people of higher age and/or with chronic conditions, TBE has higher mortality and more severe long-term consequences).

Factors of the individual

Apart from difficulty in estimating the real risk of acquiring TBE, there is another challenge; and it is the perception of safety when traveling to a European industrialized country. The majority of travelers may not seek travel advice prior to travel, or at least not early enough to be able to finish the course of vaccination.

Conclusion

The principal information a traveler should be advised of regarding TBE is that it is a febrile illness affecting the brain and spinal cord. It is transmitted by hard ticks in many countries of moderate climate in Europe and Asia. Unpasteurized milk and dairy products may also be a source of infection. The illness is rare in travelers, which may be partially due to misdiagnosis and underreporting. TBE has low mortality; however, there is a very high burden of long-term morbidity, especially neurological deficits. Tick avoidance is a particularly important factor when involved in outdoor activities, but the only proven prevention is vaccination. Vaccination may be administered in an accelerated schedule relatively shortly (several weeks) before travel. TBE vaccines are in general very effective and well tolerated.

There are various on-line resources of information concerning tick-borne diseases including TBE:

http://travelvaccination.co.uk/region/europe/

http://travelhealthpro.org.uk/tick-borne-encephalitis/

http://www.nhs.uk/Conditions/Tick-borne-encephalitis/Pages/Beforeyougopage.aspx

http://cks.nice.org.uk/immunizations-travel#!scenario:9